ArticleBMC infectious diseases2025
Clinical spectrum of Talaromyces marneffei infections in HIV-negative patients: an 18-case series including a rare presentation with gastrointestinal onset, adrenal mass, and hemophagocytic lymphohistiocytosis.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multiple recurrences of Talaromyces marneffei infection with HLH in an HIV-negative patient: a case report.BMC infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe diverse manifestations of Talaromyces marneffei (TM) infection in HIV-negative patients complicate and often delay diagnosis. This study reviews 18 cases to better characterize the clinical spectrum of this disease, with the goal of improving recognition of its varied presentations.
methodsRetrospective analysis of 18 patients assessing underlying diseases, manifestations, co-infections, diagnostics, treatment, and outcomes. Diagnosis required TM positivity via culture, histopathology, or metagenomic next-generation sequencing(mNGS).
resultsThis cohort (14 males and 4 females; mean age 57.94 ± 11.12 years) exhibited diverse comorbidities, including renal transplantation (27.8%), tuberculosis (22.2%), cancer (16.7%), bronchiectasis (16.7%), and anti-interferon-γ autoantibody (AIGA) syndrome (11.1%). Common manifestations included respiratory symptoms (72.2%), fever (55.6%), and anemia (50.0%). Immunodeficiency was frequent, with an abnormal CD4/CD8 ratio in in 10/15 patients (66.7%). Notably, 94.4% of cases were initially misdiagnosed-often as tuberculosis (35.3%) or bacterial pneumonia (23.5%)-leading to a mean diagnostic delay of 8.97 ± 7.02 weeks. mNGS provided diagnosis in 77.8% of cases. Overall mortality was 22.2%, with two relapses linked to AIGA syndrome. We report the first documented TM triad in a patient with systemic lupus erythematosus (SLE) and Epstein-Barr virus (EBV) coinfection: concurrent gastrointestinal onset (manifesting as ileocolonic ulcers), adrenal mass, and hemophagocytic lymphohistiocytosis (HLH).
conclusionsTM infection in HIV-negative hosts demonstrates broad clinical heterogeneity, often masked by comorbidities and leading to delayed diagnosis. mNGS is critical for early identification. The unprecedented triad of gastrointestinal onset, adrenal mass, and HLH underscores TM's capacity for atypical dissemination. AIGA may predict relapse. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.